American Diabetes Association: 2026 Pathway to Stop Diabetes
Apply to Internal Competition // Limit: 2 (one in basic science/preclinical research and one in translational science) // Tickets Available: 2
Limiting Langauge
Each institution is allowed a maximum of two (2) nominations per grant cycle: one (1) applicant must be focused on basic science/preclinical research and one (1) applicant must be focused on translational science. Each nomination can be for either of the Pathway Program Award types: Initiator or Accelerator. Please be aware that if an institution nominates two (2) applicants with proposed projects covering the same phase of research (i.e. basic through preclinical research studies), one of the submitted applications will be administratively disqualified from consideration for funding.
Program Summary
The Pathway to Stop Diabetes® program intends to attract brilliant scientists approaching the peak of their careers in diabetes research, and to accelerate their research progress by providing the necessary resources and support for conducting transformative science.
This call for nominations will prioritize exceptional investigators across the spectrum of diabetes research, spanning basic science through public health research and implementation science. The ideal applicant will propose innovative research with the ultimate goal of improving the lives of people at risk of diabetes or living with the disease - and the pathway to this impact is clear.
Starting in 2024, ADA will accept up to two (2) nominations per institution with one (1) nomination spanning basic through preclinical research and one (1) nomination spanning clinical through public health research.
Examples of basic through preclinical research studies (for nomination #1) include:
- Innovative mechanistic studies on fundamental or new aspects of biology
- Novel insights derived from data science using AI/Machine Learning
- Development of new technologies, devices, and/or experimental approaches
Identification and validation of novel and unique therapeutic targets
Examples of clinical through public health research (for nomination #2) include:
- Clinical experimental medicine studies
- Identification and validation of novel biomarkers
- Health services research
- Behavioral research
- Population epidemiology
- Health economics research
- Patient preference / Quality of Life
- Dissemination and implementation science
- Health Care system-based interventions
Nominations are welcomed from all areas of diabetes and span prevention, management, and cure of all diabetes types (i.e. type 1, type 2 and gestational), diabetes-related disease states (obesity, prediabetes, and other insulin resistant states) and complications. The program intends to attract a broad range of expertise to the field of diabetes from various fields of science and technology, including medicine, biology, chemistry, engineering, mathematics, and physics.